VIPR1 and breast carcinoma: Less studied targets include the gastrin-releasingpeptide receptor(GRPR) and vasoactive intestinal polypeptide receptor 1 (VIP-R1),yet their expression in breast cancer is documented (GRPR96−99 and VIP-R1100,101), and they were investigatedclinically for the detection of breast malignancies.102−104 Radiotracers used for the detection of GRPR were [68Ga]Ga-SB3,achieving 50% tumor detection (n = 8),102 and [68Ga]Ga-RM2, reaching 72% breastcancer visualization (n = 18),103 both GRPR peptide antagonists.